Kantify

Kantify is excited to report its joint progress with The Johns Hopkins University School of Medicine and Dr Ranjan Perera's lab on the discovery of drugs for prostate cancer. While a traditional small molecule discovery screening requires testing 20,000 to 100,000 molecules to find 1 hit, we have tested only 5 molecules to validate... 4. We are extremely proud of these results and are looking forward to helping patients! Congrats to Ranjan Perera Menglang Yuan Maxime Georges Nicolas Maignan Nik Subramanian David Papazian ⏩ Full article can be found as a first comment below this post.

As All.Can Belgium's homepage states: "More efficient cancer care makes a life of difference". It was therefore a real honor for our cofounder Nik Subramanian to be invited at the All.Can Belgium conference. Nik shared about Kantify's relentless efforts and excellent results to use AI to discover novel cancer therapies. Together, we can change the future of cancer treatment and care!

Can an AI technology for human drug discovery work also for plant drug discovery? This is one of the questions that our COO Nicolas Maignan tackled in Valencia a few days ago, as he gave a lecture entitled "Unlocking and Accelerating Drug Discovery with Artificial Intelligence: The Kantify Approach." Nicolas was invited by the Instituto de Biología Molecular y Celular de Plantas, IBMCP (UPV - CSIC). The IBMCP, a distinguished research institution at the forefront of plant biology and biotechnology innovation, has been a key partner of Kantify for the past two years. Together, we pioneering the discovery of plant-based therapeutic solutions. During the seminar, Nicolas presented an in-depth analysis of Sapian's unique capabilities, specifically tailored to plant-based drug discovery. Key topics included: - AI-Driven Target Identification: Employing machine learning to identify novel biological targets within complex plant systems. - Small Molecule Discovery: Optimizing the efficacy and safety of therapeutic compounds through AI-driven insights. - Case Studies: Practical applications demonstrating Sapian's success in accelerating plant drug discovery. For more information on Sapian and our AI-powered approaches to drug discovery, we encourage you to connect with us via our contact form. https://lnkd.in/dsTG6PjG Together, we can drive the future of biotechnology.

Our CEO Ségolène Martin will be speaking at Biofit tomorrow morning at the session on biotech / academia collaboration. At Kantify, collaboration is in our blood. As a TechBio we have a number of research collaborations with leading academic teams in Europe, Asia and the US. Are you also attending BioFIT and want to meet? Poke Ségolène on LinkedIn or via the BioFIT platform!

Such database on funding opportunities for drug repurposing should be interesting for our partners and followers interested in helping untreated patients with old/existing drugs ⏩ https://lnkd.in/egtB_Qxt

[TV] Our partner Xavier Nissan, Research Director at I-Stem, got interviewed this weekend on French TV at the occasion of #Telethon2024 . Xavier did a great job in explaining clearly how AFM-Téléthon , the association of patients affected by a neuromuscular disorder, uses Artificial Intelligence for the better treatment of rare neuromuscular disorders. At Kantify, we are proud to partner with people as committed as Xavier and his team, for such a meaningful project as the DREAMS project, supported by the European Commission. Together we are working to discover novel therapeutic targets and drugs for 5 neuromuscular disorders. Patients are waiting, and through our initial research work, we firmly believe that AI will help. Ps: it is not too late to support AFM-Téléthon which is running its annual fundraising campaign https://lnkd.in/gtg4ixwN Xavier Nissan Yann Guivarch Marc Peschanski Nicolas Maignan Nik Subramanian Rubal Ravinder Jean-François BRIAND Quentin MIAGOUX Mónica Pérez https://lnkd.in/eg9f7Rbr

Let’s support these courageous kids ❤️🩹 Today, the Telethon is starting. This annual fundraising event is organised by our partners of AFM-Téléthon, the organization of patients with rare neuromuscular disorders. Let’s support Telethon and through this, let’s support research for patients and families hoping for a cure. Donate - https://lnkd.in/gtg4ixwN Watch testimonials - https://lnkd.in/e2hwpszk

Exciting News! Today, we're unveiling the latest small molecule drug screened by our AI platform, Sapian. Many of you are familiar with this medication—it was the 169th most prescribed drug in the United States in 2022, with over 3 million prescriptions. This widely used drug is Diazepam, also known as Valium. In our newly published white paper, "AI for Safer Medications: A Deep Dive into Diazepam's (Valium) Risks," we have leveraged Sapian to predict unknown biological off-targets of Diazepam and uncover how they link to its known side effects. 🔍 Why is this important? - Enhanced Drug Safety: Understanding these off-targets can lead to safer prescribing practices and inform risk assessments. - Innovative Drug Discovery: Demonstrates the power of AI in uncovering hidden aspects of well-known medications. - Impactful Insights: Provides fully novel data driven hypotheses for researchers and healthcare professionals in the field. For those of you active in drug discovery and pharmacology, we highly recommend reading this study. We believe you'll find the results as striking and thought-provoking as we did. Let's listen to our colleague Jack Dawe, Machine Learning Engineer at Kantify and Lead Author of the White Paper, as he presents this second issue of our "Behind the Pill" series, entitled "AI for Safer Medications: A Deep Dive into Diazepam's (Valium) Risks." Access the White Paper here : https://lnkd.in/eTfsgb3c Nb: if you are a drug hunter with a candidate small molecule to be analyzed by Sapian, please get in touch to understand how you can identify likely side effects even before the molecule leaves your lab.

Countdown : Day - 3 until our new "Behind the Pill" release. 🧪Today, we share some clues! Kantify is about to release groundbreaking findings about a widely used pharmaceutical molecule. Leveraging our AI platform, Sapian, we've uncovered insights about its side effects. 🧪Can you identify the molecule? Here are some clues: Clue 1: This medication has been a cornerstone in clinical practice for over half a century, renowned for its efficacy in treating a variety of conditions. Clue 2: It belongs to a class of compounds that act on the central nervous system, primarily influencing neurotransmitter activity to produce calming effects. Clue 3: Its name is derived from the Latin word for "healthy" reflecting perhaps the relief it brings to those who use it. 🧪We invite you to share your thoughts and guesses in the comments below. Our detailed analysis will be published on November 26th. We believe this disclosure will add valuable insights to the fields of pharmacology and artificial intelligence. #Kantify #AI #DrugDiscovery #Offtarget

Today we celebrate a special birthday, the birthday of Sapian. Do you actually know Sapian? Sapian is a really special kind of colleague. In the team, we all work with Sapian every day. We work hard to help it grow, develop itself, week after week. Sapian is actually ... Kantify's AI technology for drug discovery 😊 Because Sapian is so important, and has been so helpful discovering new therapeutic targets and drugs in the past few years, we wanted to celebrate its birthday. This is why we used AI (obviously!) to create an Ode in its honor. "Ode to Sapian" In the depths of molecules, secrets reside, Proteins and pathways where mysteries hide. Sapian ventures where others have failed, Mapping the unknown where science has trailed. It predicts the hits, the targets, the way, Unveiling connections in intricate play. From proteins to drugs, it weaves a grand net, A tool for discovery the future has met. For phenotypes known, or assays obscure, Its learnings rupture, its insights are pure. Sapian, the guide in the quest for the cure, Through AI’s lens, it helps us endure 🎂 Happy Birthday, fantastic Sapian, and to many more years of helping patients together! David PapazianCaio Hudson Queiroz de Souza Nik Subramanian Nicolas Maignan Rubal Ravinder Ségolène Martin Jack Dawe Maxime Georges